Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

701
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
701
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

261
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
261
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

215
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
215
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

253
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
253
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.3K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.3K
Aging01:26

Aging

701
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
701

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Design and analysis strategies for robust microbiome ageing research.

FEBS letters·2026
Same author

Evolutionary genetics of ageing.

Nature reviews. Genetics·2026
Same author

Aging-associated decline of phosphatidylcholine synthesis is a malleable trigger of natural mitochondrial aging.

Nature communications·2026
Same author

Spontaneous aging-associated inflammation and genome instability in the immune system of turquoise killifish.

Nature aging·2026
Same author

Past, present and future perspectives on the science of aging.

Nature aging·2026
Same author

Age-Dependent Gut Microbiota Dynamics and Their Association with Male Life-History Traits in Drosophila melanogaster.

Microbial ecology·2025

Related Experiment Video

Updated: Jan 31, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K

Identifying Potential Ageing-Modulating Drugs In Silico.

Handan Melike Dönertaş1, Matías Fuentealba2, Linda Partridge3

  • 1European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton CB10 1SD, UK; These authors contributed equally to this work.

Trends in Endocrinology and Metabolism: TEM
|December 25, 2018
PubMed
Summary

Aging is a malleable process, and drugs may delay age-related diseases. This review explores computational strategies to identify anti-aging drugs for better healthspan.

Keywords:
ageingcomputational biologydrug repurposinglongevity

More Related Videos

A Fluorescent Screening Assay for Identifying Modulators of GIRK Channels
05:31

A Fluorescent Screening Assay for Identifying Modulators of GIRK Channels

Published on: April 24, 2012

14.9K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.6K

Related Experiment Videos

Last Updated: Jan 31, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K
A Fluorescent Screening Assay for Identifying Modulators of GIRK Channels
05:31

A Fluorescent Screening Assay for Identifying Modulators of GIRK Channels

Published on: April 24, 2012

14.9K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.6K

Area of Science:

  • Gerontology
  • Pharmacology
  • Computational Biology

Background:

  • Increased human life expectancy leads to greater healthcare challenges.
  • Aging is associated with chronic diseases, multimorbidity, and polypharmacy.
  • Laboratory studies indicate aging is a modifiable process.

Purpose of the Study:

  • To review existing studies on drugs that modulate the aging process.
  • To explore computational drug-repurposing strategies for novel anti-aging therapeutics.
  • To identify interventions that may delay or prevent age-related diseases.

Main Methods:

  • Review of published literature on drug repurposing for aging.
  • Analysis of studies investigating genetic and environmental interventions in aging.
  • Exploration of computational approaches to identify potential anti-aging drugs.

Main Results:

  • Evidence suggests certain drugs can modulate the aging process.
  • Computational drug-repurposing strategies show promise for discovering anti-aging agents.
  • Existing medications may hold potential for improving health in late life.

Conclusions:

  • Modulating the aging process with drugs could prevent multiple age-related diseases.
  • Future research should integrate multi-omics and health data for drug prediction.
  • Developing drugs to improve healthspan is crucial for aging populations.